M8 Holdings

M8 Pharmaceuticals is a specialty pharmaceutical company focused on licensing, marketing, and distributing innovative therapeutic products in Latin America, specifically Mexico and Brazil. The company partners with global pharmaceutical and biotech firms to bring high-value treatments to patients in therapeutic areas such as central nervous system (CNS), gastroenterology, oncology, and rare diseases. In 2023, M8 was acquired by Acino, a Swiss-based pharmaceutical company, to strengthen its presence in the Latin American region. M8 provides end-to-end solutions including regulatory affairs, market access, and commercial execution. The company's portfolio includes several high-profile licensed products such as Nurtec ODT for migraine and various treatments for ADHD and metabolic disorders.